Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused over 5 million deaths to date. Although multiple vaccines are available, breakthrough infections occur especially by emerging variants. Effective therapeutic options such as monoclonal antibodies (mAbs) are still critical. Here, we report the development, cryo-EM structures, and functional analyses of mAbs that potently neutralize SARS-CoV-2 variants of concern. By high-throughput single cell sequencing of B cells from spike receptor binding domain (RBD) immunized animals, we identified two highly potent SARS-CoV-2 neutralizing mAb clones that have single-digit nanomolar affinity and low-picomolar avidity, and generated a bispecific antibody. Lead antibodies showed strong inhibitory activity against historical SARS-CoV-2 and several emerging variants of concern. We solved several cryo-EM structures at ∼3 Å resolution of these neutralizing antibodies in complex with prefusion spike trimer ectodomain, and revealed distinct epitopes, binding patterns, and conformations. The lead clones also showed potent efficacy in vivo against authentic SARS-CoV-2 in both prophylactic and therapeutic settings. We also generated and characterized a humanized antibody to facilitate translation and drug development. The humanized clone also has strong potency against both the original virus and the B.1.617.2 Delta variant. These mAbs expand the repertoire of therapeutics against SARS-CoV-2 and emerging variants.
| Errataetall: |
UpdateIn: Nat Commun. 2022 Mar 28;13(1):1638. - PMID 35347138 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2021) vom: 24. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Peng, Lei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 05.11.2023 published: Electronic UpdateIn: Nat Commun. 2022 Mar 28;13(1):1638. - PMID 35347138 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2021.12.21.473733 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335165192 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335165192 | ||
| 003 | DE-627 | ||
| 005 | 20231225225235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.12.21.473733 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335165192 | ||
| 035 | |a (NLM)34981065 | ||
| 035 | |a (PII)2021.12.21.473733 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Peng, Lei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Nat Commun. 2022 Mar 28;13(1):1638. - PMID 35347138 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused over 5 million deaths to date. Although multiple vaccines are available, breakthrough infections occur especially by emerging variants. Effective therapeutic options such as monoclonal antibodies (mAbs) are still critical. Here, we report the development, cryo-EM structures, and functional analyses of mAbs that potently neutralize SARS-CoV-2 variants of concern. By high-throughput single cell sequencing of B cells from spike receptor binding domain (RBD) immunized animals, we identified two highly potent SARS-CoV-2 neutralizing mAb clones that have single-digit nanomolar affinity and low-picomolar avidity, and generated a bispecific antibody. Lead antibodies showed strong inhibitory activity against historical SARS-CoV-2 and several emerging variants of concern. We solved several cryo-EM structures at ∼3 Å resolution of these neutralizing antibodies in complex with prefusion spike trimer ectodomain, and revealed distinct epitopes, binding patterns, and conformations. The lead clones also showed potent efficacy in vivo against authentic SARS-CoV-2 in both prophylactic and therapeutic settings. We also generated and characterized a humanized antibody to facilitate translation and drug development. The humanized clone also has strong potency against both the original virus and the B.1.617.2 Delta variant. These mAbs expand the repertoire of therapeutics against SARS-CoV-2 and emerging variants | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Hu, Yingxia |e verfasserin |4 aut | |
| 700 | 1 | |a Mankowski, Madeleine C |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Rita E |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Tongqing |e verfasserin |4 aut | |
| 700 | 1 | |a Tripler, Therese |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Lupeng |e verfasserin |4 aut | |
| 700 | 1 | |a Chow, Ryan D |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Zhenhao |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Chunxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Matthew B |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Guilin |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Bryce |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Daryl |e verfasserin |4 aut | |
| 700 | 1 | |a Sutton, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Diamond, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Wilen, Craig B |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Sidi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2021) vom: 24. Dez. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:24 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.12.21.473733 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 24 |c 12 | ||